CytomX Therapeutics (NASDAQ:CTMX) Sets New 52-Week High After Analyst Upgrade

CytomX Therapeutics, Inc. (NASDAQ:CTMX)’s share price reached a new 52-week high during mid-day trading on Monday after Wedbush raised their price target on the stock from $6.00 to $11.00. Wedbush currently has an outperform rating on the stock. CytomX Therapeutics traded as high as $7.74 and last traded at $7.28, with a volume of 57367736 shares. The stock had previously closed at $4.68.

Several other analysts have also recently issued reports on CTMX. Barclays upped their target price on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Cantor Fitzgerald boosted their price objective on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 4th. Oppenheimer restated an “outperform” rating and set a $12.00 price objective on shares of CytomX Therapeutics in a research report on Monday. Piper Sandler raised their price objective on CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Finally, HC Wainwright lifted their target price on CytomX Therapeutics from $10.00 to $17.00 and gave the stock a “buy” rating in a report on Monday. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.50.

Key Stories Impacting CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 Varseta‑M expansion showed meaningful activity in heavily pretreated metastatic colorectal cancer (32% response rate at 10 mg/kg Q3W; estimated PFS ~7.1 months) with a manageable safety profile and planned FDA discussions to align on potential registrational trial — this is the primary catalyst for the earlier rally. Read More.
• Positive Sentiment: Multiple firms upgraded or raised price targets after the data (examples: Wedbush, HC Wainwright, JPMorgan noted higher PTs and upgraded ratings), which amplified buying interest and momentum. Read More.
• Neutral Sentiment: Company released its Q4 materials, slide deck and hosted an earnings call discussing the clinical progress and next‑steps (including combination studies and timelines) — useful context for longer‑term investors assessing pathway to a registrational study. Read More.
• Negative Sentiment: CytomX filed for an underwritten public offering to raise $250M (common stock and pre‑funded warrants) — a near‑term dilution risk that likely pressured the stock after the initial data‑driven surge. Read More.
• Negative Sentiment: Q4 results missed expectations (EPS and revenue; EPS -$0.22 vs. est. -$0.08; revenue ~$0.66M vs. est. ~$7.33M), which reinforces near‑term funding needs and contributed to selling pressure. Read More.

Hedge Funds Weigh In On CytomX Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Boothbay Fund Management LLC purchased a new stake in shares of CytomX Therapeutics in the third quarter worth approximately $3,946,000. Precision Wealth Strategies LLC purchased a new position in CytomX Therapeutics during the 3rd quarter valued at $756,000. Baker BROS. Advisors LP boosted its holdings in CytomX Therapeutics by 22.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 4,250,826 shares of the biotechnology company’s stock valued at $13,560,000 after acquiring an additional 766,600 shares during the period. Inspire Investing LLC bought a new position in CytomX Therapeutics in the 3rd quarter valued at $1,667,000. Finally, Vivo Capital LLC bought a new position in CytomX Therapeutics in the 2nd quarter valued at $13,096,000. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Stock Down 19.3%

The business has a 50 day simple moving average of $5.26 and a two-hundred day simple moving average of $4.09. The firm has a market cap of $923.39 million, a PE ratio of -136.25 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The company had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $7.33 million. CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 20.65%. Equities analysts forecast that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current year.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.